Detalhe da pesquisa
1.
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 401(10388): 1571-1583, 2023 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37116523
2.
Edoxaban versus warfarin in patients with atrial fibrillation.
N Engl J Med
; 369(22): 2093-104, 2013 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24251359
3.
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
Am Heart J
; 170(4): 669-74, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26386790
4.
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Am Heart J
; 160(4): 635-41, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20934556
5.
Effect of ACAT inhibition on the progression of coronary atherosclerosis.
N Engl J Med
; 354(12): 1253-63, 2006 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-16554527
6.
Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects.
J Am Coll Cardiol
; 39(12): 2034-41, 2002 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-12084605